AR105313A1 - Anticuerpo anti-cd137 terapéutico - Google Patents
Anticuerpo anti-cd137 terapéuticoInfo
- Publication number
- AR105313A1 AR105313A1 ARP160100459A ARP160100459A AR105313A1 AR 105313 A1 AR105313 A1 AR 105313A1 AR P160100459 A ARP160100459 A AR P160100459A AR P160100459 A ARP160100459 A AR P160100459A AR 105313 A1 AR105313 A1 AR 105313A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- antibody
- sequence
- chain variable
- variable domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Reivindicación 1: Un anticuerpo completamente humano anti-CD137 aislado de una clase de IgG que se une a un epitope de CD137, en donde dicho anticuerpo comprende una secuencia de dominio variable de cadena pesada que es por lo menos 95% idéntica a una secuencia de aminoácidos que se elige del grupo que consiste en SEQ ID Nº 1, SEQ ID Nº 3, SEQ ID Nº 5, SEQ ID Nº 6, SEQ ID Nº 7, SEQ ID Nº 9, SEQ ID Nº 11, SEQ ID Nº 13, SEQ ID Nº 15, SEQ ID Nº 17, SEQ ID Nº 19, SEQ ID Nº 21, SEQ ID Nº 23, SEQ ID Nº 25, SEQ ID Nº 27, SEQ ID Nº 29, SEQ ID Nº 31, SEQ ID Nº 33, SEQ ID Nº 35, SEQ ID Nº 37, SEQ ID Nº 39, SEQ ID Nº 41, SEQ ID Nº 43, SEQ ID Nº 45, SEQ ID Nº 47, SEQ ID Nº 49, SEQ ID Nº 51, SEQ ID Nº 53, SEQ ID Nº 55, SEQ ID Nº 57, SEQ ID Nº 59, SEQ ID Nº 61, SEQ ID Nº 63, SEQ ID Nº 65, SEQ ID Nº 67, SEQ ID Nº 69, SEQ ID Nº 71, SEQ ID Nº 73, SEQ ID Nº 75, SEQ ID Nº 77, SEQ ID Nº 79, SEQ ID Nº 81, SEQ ID Nº 83, SEQ ID Nº 85, SEQ ID Nº 87, SEQ ID Nº 89, SEQ ID Nº 91, SEQ ID Nº 93, SEQ ID Nº 95, SEQ ID Nº 97, SEQ ID Nº 99, SEQ ID Nº 101, SEQ ID Nº 103, SEQ ID Nº 105, SEQ ID Nº 107, SEQ ID Nº 109, SEQ ID Nº 111, SEQ ID Nº 113, SEQ ID Nº 115, SEQ ID Nº 117, SEQ ID Nº 119, SEQ ID Nº 121, SEQ ID Nº 123, SEQ ID Nº 125, SEQ ID Nº 127, SEQ ID Nº 129, SEQ ID Nº 130, SEQ ID Nº 131, SEQ ID Nº 132, SEQ ID Nº 133, SEQ ID Nº 134, SEQ ID Nº 135, SEQ ID Nº 136, SEQ ID Nº 137, SEQ ID Nº 138, SEQ ID Nº 139, SEQ ID Nº 140, SEQ ID Nº 141, SEQ ID Nº 142, SEQ ID Nº 143; y una secuencia de dominio variable de cadena liviana que es por lo menos 95% idéntica a la secuencia de aminoácidos que se elige del grupo que consiste en SEQ ID Nº 2, SEQ ID Nº 4, SEQ ID Nº 6, SEQ ID Nº 8, SEQ ID Nº 10, SEQ ID Nº 12, SEQ ID Nº 14, SEQ ID Nº 16, SEQ ID Nº 18, SEQ ID Nº 20, SEQ ID Nº 22, SEQ ID Nº 24, SEQ ID Nº 26, SEQ ID Nº 28, SEQ ID Nº 30, SEQ ID Nº 32, SEQ ID Nº 34, SEQ ID Nº 36, SEQ ID Nº 38, SEQ ID Nº 40, SEQ ID Nº 42, SEQ ID Nº 44, SEQ ID Nº 46, SEQ ID Nº 48, SEQ ID Nº 50, SEQ ID Nº 52, SEQ ID Nº 54, SEQ ID Nº 56, SEQ ID Nº 58, SEQ ID Nº 60, SEQ ID Nº 62, SEQ ID Nº 64, SEQ ID Nº 66, SEQ ID Nº 68, SEQ ID Nº 70, SEQ ID Nº 72, SEQ ID Nº 74, SEQ ID Nº 76, SEQ ID Nº 78, SEQ ID Nº 80, SEQ ID Nº 82, SEQ ID Nº 84, SEQ ID Nº 86, SEQ ID Nº 88, SEQ ID Nº 90, SEQ ID Nº 92, SEQ ID Nº 94, SEQ ID Nº 96, SEQ ID Nº 98, SEQ ID Nº 100, SEQ ID Nº 102, SEQ ID Nº 104, SEQ ID Nº 106, SEQ ID Nº 108, SEQ ID Nº 110, SEQ ID Nº 112, SEQ ID Nº 114, SEQ ID Nº 116, SEQ ID Nº 118, SEQ ID Nº 120, SEQ ID Nº 122, SEQ ID Nº 124, SEQ ID Nº 126, y SEQ ID Nº 128. Reivindicación 10: Un método para tratar cáncer en un sujeto que lo necesite, en donde el método comprende administrar una cantidad eficaz del anticuerpo o fragmento de anticuerpo de cualquiera de las reivindicaciones 1 a 9, de forma de tratar dicho cáncer. Reivindicación 16: Una composición farmacéutica que comprende el anticuerpo anti-CD137, o fragmento de anticuerpo de cualquiera de las reivindicaciones 1 a 9 ó 15, y un transportador farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119211P | 2015-02-22 | 2015-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105313A1 true AR105313A1 (es) | 2017-09-27 |
Family
ID=56690285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100459A AR105313A1 (es) | 2015-02-22 | 2016-02-23 | Anticuerpo anti-cd137 terapéutico |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10259881B2 (es) |
| EP (1) | EP3258959A4 (es) |
| JP (1) | JP2018508509A (es) |
| KR (1) | KR20180016972A (es) |
| CN (1) | CN107921104A (es) |
| AR (1) | AR105313A1 (es) |
| AU (1) | AU2016219772A1 (es) |
| CA (1) | CA2977257A1 (es) |
| IL (1) | IL254088A0 (es) |
| MX (1) | MX2017010793A (es) |
| TW (1) | TW201632559A (es) |
| WO (1) | WO2016134358A1 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| JP2018508509A (ja) * | 2015-02-22 | 2018-03-29 | ソレント・セラピューティクス・インコーポレイテッド | Ｃｄ１３７に結合する抗体医薬 |
| MX2017014699A (es) * | 2015-05-21 | 2018-04-11 | Alligator Bioscience Ab | Polipeptidos novedosos. |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US11091557B2 (en) | 2016-07-14 | 2021-08-17 | Genmab A/S | Methods of producing multispecific antibodies against CD40 and CD137 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| GB201619648D0 (en) * | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| US10899842B2 (en) | 2016-11-23 | 2021-01-26 | Immunoah Therapeutics, Inc. | 4-1BB binding proteins and uses thereof |
| US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
| RU2725811C1 (ru) | 2017-01-06 | 2020-07-06 | Ютайлекс Ко., Лтд. | Антитела против 4-1bb человека и их применение |
| JP6827113B2 (ja) | 2017-01-21 | 2021-02-10 | 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． | シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用 |
| AU2018224094A1 (en) | 2017-02-24 | 2019-09-19 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| EP3609921A2 (en) * | 2017-04-13 | 2020-02-19 | Agenus Inc. | Anti-cd137 antibodies and methods of use thereof |
| PE20200757A1 (es) | 2017-07-11 | 2020-07-27 | Compass Therapeutics Llc | Anticuerpos agonistas que se unen a cd137 humano y sus usos |
| CA3071383C (en) | 2017-08-01 | 2022-04-12 | Eli Lilly And Company | Anti-cd137 antibodies |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
| CA3075969A1 (en) * | 2017-10-10 | 2019-04-18 | Numab Therapeutics AG | Multispecific antibody |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| TWI701259B (zh) * | 2017-11-09 | 2020-08-11 | 大陸商上海懷越生物科技有限公司 | ４﹘１ｂｂ抗體及其製備方法和應用 |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019104716A1 (en) * | 2017-12-01 | 2019-06-06 | Adagene Inc. | Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody |
| CA3086098A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| SG11202007678QA (en) * | 2018-02-23 | 2020-09-29 | Bicycletx Ltd | Multimeric bicyclic peptide ligands |
| EP3797120A1 (en) | 2018-05-21 | 2021-03-31 | Compass Therapeutics LLC | Compositions and methods for enhancing the killing of target cells by nk cells |
| JP2021529520A (ja) * | 2018-06-29 | 2021-11-04 | アレクトル エルエルシー | 抗ｓｉｒｐ−ベータ１抗体及びその使用方法 |
| US11939381B2 (en) | 2018-07-19 | 2024-03-26 | Eli Lilly And Company | Bispecific antibodies targeting immune checkpoints |
| EP3850012A4 (en) * | 2018-09-12 | 2022-06-15 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-TNFRSF9 ANTIBODIES AND THEIR USES |
| WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| US20220056136A1 (en) * | 2018-11-30 | 2022-02-24 | Abl Bio Inc. | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
| JP2022516301A (ja) * | 2019-01-02 | 2022-02-25 | キューエルエスエフ バイオセラピューティック インコーポレイテッド | Ｃｄ１３７アゴニスト性抗体とその使用 |
| BR112021016791A2 (pt) * | 2019-02-26 | 2021-11-16 | Sorrento Therapeutics Inc | Proteínas de ligação de antígenos que se ligam a bcma |
| CA3137373A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| EP3980448A4 (en) * | 2019-06-04 | 2023-06-28 | Academia Sinica | Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors |
| AU2020308463A1 (en) * | 2019-06-26 | 2022-02-17 | Ap Biosciences, Inc. | Antibodies for T-cell activation |
| EP4041772A4 (en) * | 2019-10-11 | 2024-04-24 | Nanjing Leads Biolabs Co Ltd | 4-1BB-BINDING ANTIBODIES AND USES THEREOF |
| JP2023522024A (ja) * | 2020-04-17 | 2023-05-26 | ディンフー バイオターゲット カンパニー リミテッド | Ｃｄ１３７と特異的に結合する製剤とその使用について |
| CN113842456B (zh) * | 2020-06-28 | 2022-07-26 | 上海齐鲁制药研究中心有限公司 | 一种抗人4-1bb的单克隆抗体制剂及其用途 |
| WO2023098785A1 (zh) * | 2021-12-01 | 2023-06-08 | 上海君实生物医药科技股份有限公司 | 抗4-1bb抗体及其用途 |
| CN115975032A (zh) * | 2022-12-19 | 2023-04-18 | 华润生物医药有限公司 | 一种cldn18.2抗体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0302525A2 (hu) * | 2001-01-05 | 2003-10-28 | Abgenix, Inc. | Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok |
| DE60232895D1 (de) * | 2001-10-09 | 2009-08-20 | Mayo Foundation | Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort |
| US20030223989A1 (en) | 2002-04-18 | 2003-12-04 | Pluenneke John D. | CD137 agonists to treat patients with IgE-mediated conditions |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| EP2399935A3 (en) | 2005-02-15 | 2012-02-22 | GTC Biotherapeutics, Inc. | An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| SG10201506906VA (en) * | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
| MY166429A (en) * | 2010-11-17 | 2018-06-26 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| JP2018508509A (ja) | 2015-02-22 | 2018-03-29 | ソレント・セラピューティクス・インコーポレイテッド | Ｃｄ１３７に結合する抗体医薬 |
| EP3265486A4 (en) * | 2015-03-06 | 2018-11-14 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind tim3 |
| US20200048350A1 (en) * | 2018-07-24 | 2020-02-13 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| WO2020077257A1 (en) * | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
-
2016
- 2016-02-22 JP JP2017544293A patent/JP2018508509A/ja not_active Withdrawn
- 2016-02-22 MX MX2017010793A patent/MX2017010793A/es unknown
- 2016-02-22 CA CA2977257A patent/CA2977257A1/en not_active Abandoned
- 2016-02-22 WO PCT/US2016/018897 patent/WO2016134358A1/en active Application Filing
- 2016-02-22 KR KR1020177026952A patent/KR20180016972A/ko unknown
- 2016-02-22 TW TW105105159A patent/TW201632559A/zh unknown
- 2016-02-22 EP EP16753215.9A patent/EP3258959A4/en not_active Withdrawn
- 2016-02-22 CN CN201680022446.1A patent/CN107921104A/zh active Pending
- 2016-02-22 US US15/050,215 patent/US10259881B2/en active Active
- 2016-02-22 US US15/049,718 patent/US10233251B2/en active Active
- 2016-02-22 AU AU2016219772A patent/AU2016219772A1/en not_active Abandoned
- 2016-02-23 AR ARP160100459A patent/AR105313A1/es unknown
-
2017
- 2017-08-21 IL IL254088A patent/IL254088A0/en unknown
-
2019
- 2019-02-08 US US16/270,761 patent/US11180568B2/en active Active
-
2021
- 2021-10-12 US US17/499,127 patent/US20220025064A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3258959A4 (en) | 2018-10-17 |
| US10233251B2 (en) | 2019-03-19 |
| US20220025064A1 (en) | 2022-01-27 |
| TW201632559A (zh) | 2016-09-16 |
| CN107921104A (zh) | 2018-04-17 |
| US10259881B2 (en) | 2019-04-16 |
| EP3258959A1 (en) | 2017-12-27 |
| WO2016134358A1 (en) | 2016-08-25 |
| KR20180016972A (ko) | 2018-02-20 |
| US20170226215A1 (en) | 2017-08-10 |
| US20160244528A1 (en) | 2016-08-25 |
| US20190161554A1 (en) | 2019-05-30 |
| JP2018508509A (ja) | 2018-03-29 |
| US11180568B2 (en) | 2021-11-23 |
| MX2017010793A (es) | 2018-07-06 |
| CA2977257A1 (en) | 2016-08-25 |
| AU2016219772A1 (en) | 2017-09-21 |
| IL254088A0 (en) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| AR099698A1 (es) | Anticuerpos contra el c5 que tienen farmacocinética mejorada | |
| CL2022000328A1 (es) | Anticuerpo humanizado que se une específicamente al receptor de transferrina humano (tfr); composición farmacéutica; uso del anticuerpo humanizado para preparar un medicamento útil para tratar un trastorno neurológico. (divisional solicitud no. 3207-2017) | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20190975A1 (es) | Novela cd47 anticuerpos monoclonales y sus usos | |
| AR111207A1 (es) | Anticuerpos anti-lag3 | |
| PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| AR107290A1 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
| AR085281A1 (es) | Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso | |
| AR110526A1 (es) | Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| PE20161390A1 (es) | Anticuerpos multiespecificos | |
| AR091701A1 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| PE20181176A1 (es) | Composiciones biofarmaceuticas | |
| AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| AR102595A1 (es) | Anticuerpos anti-ang2 y métodos de utilización | |
| AR096601A1 (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |